{"id":"NCT05297565","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection","officialTitle":"A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Subcutaneous (Nivo SC) Versus Intravenous (Nivo IV) Administration in Participants With Stage IIIA/B/C/D or Stage IV Adjuvant Melanoma Following Complete Resection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-02","primaryCompletion":"2024-02-08","completion":"2024-02-08","firstPosted":"2022-03-28","resultsPosted":"2025-02-27","lastUpdate":"2025-02-27"},"enrollment":14,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab/rHuPH20","otherNames":["BMS-986298"]},{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558","Opdivo"]}],"arms":[{"label":"Arm A: Subcutaneous Nivolumab","type":"EXPERIMENTAL"},{"label":"Arm B: Intravenous Nivolumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose to 100 days post last dose (Approximately up to 14 Months)","effectByArm":[{"arm":"Arm A","deltaMin":6,"sd":null},{"arm":"Arm B","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":16,"countries":["United States","Australia","Belgium","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm","https://www.bmsstudyconnect.com/s/US/English/USenHome"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Asthenia","Diarrhoea","Cough","Pruritus","Hypertension"]}}